+

WO2006106994A1 - Medicament pour maladie parodontale comprenant un composant extrait de aesculus hippocastanum l. - Google Patents

Medicament pour maladie parodontale comprenant un composant extrait de aesculus hippocastanum l. Download PDF

Info

Publication number
WO2006106994A1
WO2006106994A1 PCT/JP2006/306978 JP2006306978W WO2006106994A1 WO 2006106994 A1 WO2006106994 A1 WO 2006106994A1 JP 2006306978 W JP2006306978 W JP 2006306978W WO 2006106994 A1 WO2006106994 A1 WO 2006106994A1
Authority
WO
WIPO (PCT)
Prior art keywords
periodontal disease
periodontal
oil
gingival
agent
Prior art date
Application number
PCT/JP2006/306978
Other languages
English (en)
Japanese (ja)
Other versions
WO2006106994A8 (fr
Inventor
Keisuke Kajita
Young-Soo Kim
Hideaki Kitagori
Original Assignee
Kobayashi Pharmaceutical Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kobayashi Pharmaceutical Co., Ltd. filed Critical Kobayashi Pharmaceutical Co., Ltd.
Publication of WO2006106994A1 publication Critical patent/WO2006106994A1/fr
Publication of WO2006106994A8 publication Critical patent/WO2006106994A8/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/77—Sapindaceae (Soapberry family), e.g. lychee or soapberry
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783—Angiosperms [Magnoliophyta]
    • A61K8/9789—Magnoliopsida [dicotyledons]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses

Definitions

  • the present invention relates to a novel agent for periodontal disease that inhibits abnormal extension of gingival epithelial tissue involved in the cause of oral diseases such as gingivitis and periodontitis (periodontal disease).
  • Periodontal tissue that surrounds the tooth neck and root of a mammalian tooth is composed of gingiva (gum), periodontal ligament, cementum, and alveolar bone, and plays a role in supporting the tooth. Inflammatory symptoms appear in this periodontal tissue, and the inflamed area stops at the gingiva, which is called “gingivitis”, and the inflamed area extends beyond the gingiva to the periodontal ligament and alveolar bone. The state that has reached is distinguished from "periodontitis”. In both gingivitis and periodontitis, inflammation in the periodontal tissue is affected by plaques formed by the growth of bacteria attached to food residues in the oral cavity and other environmental factors.
  • gingivitis Due to As for gingivitis, the site of inflammation is limited to the gingiva, and inflammation has not spread to the periodontal ligament or alveolar bone. Can be relieved or cured.
  • the connective tissue adhesion between the gingiva and the tooth is lost, so not only the tooth swings but also the periodontal ligament and alveolar bone. Injury's destruction and simply physically cleaning the oral cavity will make it difficult to expect periodontitis to recover.
  • the gingival epithelial cells expand toward the root of the tooth (down-gloss), resulting in a periodontitis that is characteristic between the gum and the tooth. Gingival sulcus, the so-called periodontal pocket, is formed.
  • macrolide antibiotics specifically, lactone ring is used.
  • 14-membered to 16-membered substances such as erythromycins, 16-membered macrolide josamycins, clarithromycins and the like.
  • 14-membered macrolide antibiotics are useful because they can effectively prevent and eliminate biofilm formation.
  • MMP matrix meta-oral protease
  • MMP plays a central role in the degradation of extracellular matrix in various pathologies such as cancer (cancer) disease, ulceration, rheumatoid arthritis, and osteoporosis.
  • cancer cancer
  • MMP-3 stromelysin
  • MMP-9 gelatinase
  • collagenase is not normally produced from epithelial cells, but it has been reported that it is expressed around the adhering epithelium and periodontal pocket epithelium of periodontal tissue (see Non-Patent Document 3).
  • gelatinase has been reported to be produced by epithelial cell force due to stimulation by lipopolysaccharide derived from periodontal disease-causing bacteria and to degrade type IV collagen, which is a component of the basement membrane.
  • this suggests that the increase in MMP activity is closely correlated with the progression of periodontal disease.
  • the amount of MMP contained in the mouth washes, gingival crevicular fluid and saliva of periodontal patients reflects the pathology of periodontal patients.
  • Non-Patent Document 4 A decrease in the amount of MMP has also been reported (see Non-Patent Document 4).
  • the amount of MMP and TIMP held by gingivitis patients and healthy subjects were measured, the amount of MMP in gingivitis patients was very high, and the amount of MMP in patients with periodontitis also increased. was also reported to be significant (non-patented) (Ref. 5). Therefore, substances that inhibit MMP enzyme activity and MMP production are considered to be useful in promoting the suppression of the progression of periodontal diseases associated with local inflammation.
  • Non-Patent Document 1 Nakata, Okada, "Respiration", 18, 4, pp.365-371 (1999)
  • Non-Patent Document 2 Yoshihara, Shinna, “Inflammation and Immunity", 2, pp.177-185 (1994)
  • Non-Patent Document 3 M. Kylmaniemi, et al: J. Dent Res., 75, pp. 919-926 (1996)
  • Non-Patent Document 4 M. Makela, et al: J. Dent Res., 73, pp. 1397-1406 (1994)
  • Non-Patent Document 5 A. Haerian, et al: J. ClinPeriodontoL, 22, pp.505-509 (1995) Disclosure of the Invention
  • the present invention inhibits the abnormal extension of gingival epithelial tissue in mammals and prevents the formation of periodontal pockets, thereby effectively inhibiting the progression of oral diseases such as periodontitis.
  • the purpose is to provide a new agent for periodontal disease that maintains healthy gingival tissue.
  • the gist of the present invention is that, in addition to being a well-known medicinal plant from ancient times, Aesculus hippocastanum, which has been confirmed to be safe for humans, is extracted with a solvent. It is an agent for periodontal disease which contains the obtained separated component and inhibits abnormal extension of gingival epithelial tissue in mammals. Moreover, according to the other aspect of this invention, the composition for oral cavity containing the periodontal disease agent of this invention is also provided.
  • a novel agent for periodontal disease that can inhibit the abnormal extension of the gingival epithelial thread and tissue and can effectively suppress the formation of periodontal pockets is realized.
  • a periodontal disease agent of the present invention contains an isolated component obtained by extracting Aesculus hippocastanum with a solvent and inhibits abnormal extension of gingival epithelial tissue in a mammal.
  • a disease agent is provided.
  • the term “gingival epithelial cells” refers to epithelial cells of the oral cavity mucosa (oral cavity) that surround the tooth neck and root and serve as a supporting structure for adjacent tissues. This epithelial cell adheres to the surface of the tooth enamel layer and forms a periodontal pocket as the periodontitis progresses.
  • the oral mucosal epithelial cells are always placed in an environment that is exposed to the risk of infection by bacteria, and therefore, the oral mucosal epithelial cells in other parts of the oral cavity are excellent, such as cell division. It has a distinction from the nature it has.
  • the cypress (Aesculus hippoca stanum L.), which provides an active ingredient in the agent for periodontal disease of the present invention, is a deciduous tree that originates from the northern part of Greece and comes from the Turkish region. Contains ingredients that quickly relieve swelling caused by inflammation during trauma!
  • This cypress is applied to an extraction process using a solvent.
  • the cypress or any of its parts eg branches, leaves, stems, husks, fruits or roots
  • the powder can be dried and pulverized and processed into powder, and the force can be applied to the extraction process.
  • a solvent known in the art can be used, and for example, a lower alcohol, a polyhydric alcohol, a nonpolar solvent, a polar solvent, and the like can be used.
  • Examples of lower alcohols include alcohols having 1 to 4 carbon atoms such as methanol, ethanol, propanol, isopropyl alcohol, and butanol; examples of polyhydric alcohols include glycerin and polyethylene glycol; examples of nonpolar solvents include pentane. Saturated hydrocarbons such as hexane, heptane, octane, nonane and decane; polar solvents include water, warm water (hot water), acetone, ethyl acetate, and methyl acetate.
  • the solvent it is possible to select and use only one of the above-mentioned solvents, and it is also possible to use a combination of two or more kinds of solvents. For example, in the case of using a raw material with a large amount of fat, it may be degreased and extracted with a non-polar solvent and then extracted with an arbitrary solvent or with water The extraction treatment can also be performed using a solvent.
  • Japanese cypress As a method for extracting Japanese cypress, methods well known in the art can be used. For example, Japanese cypress itself, its coarsely pulverized or cut product, or its dried crushed product (powder) is immersed in a solvent by cold immersion, digestion, etc., or while heated and stirred. A method of performing extraction and obtaining an extract containing a desired separation component through filtration, and a bar-collation method can also be used.
  • the extract obtained in this manner is used as it is, or the solvent is distilled off, depending on the mode of use, after removing unnecessary solid matter by filtration or centrifugation as necessary. And partially concentrated or dried.
  • the isolated product obtained by concentration or drying may be used after being purified by washing with a non-soluble solvent, or may be used by further dissolving or suspending the product in an appropriate solvent. You can also.
  • a fraction having a desired inhibitory activity is obtained and purified by using a conventional purification method such as a countercurrent distribution method or liquid chromatography. It is also possible to use it.
  • the solvent extract obtained as described above can be processed into a dried concentrated extract form by ordinary drying means such as reduced pressure drying or freeze drying.
  • an oral composition comprising the periodontal disease agent of the present invention as an active ingredient.
  • the periodontal disease agent of the present invention as an active ingredient.
  • other components generally used in oral compositions such as adhesives, cooling agents, Binders, sweeteners, flavorings, disintegrants, lubricants, colorants, sustained release regulators, surfactants, solubilizers, wetting agents, pH adjusters, etc. can be added optionally.
  • Examples of the pressure-sensitive adhesive include water-soluble polymer substances derived from polysaccharides, cellulose polymer substances, synthetic polymer substances, natural polymer substances, amino acid polymer substances, rubber polymer substances, and the like. Is available.
  • pullulan, pullulan derivatives, and polysaccharides such as starch; hydroxypropyl cellulose, hydroxyethyl cellulose, hydroxypropyl methenoresenorelose, hydroxyethino retino leneno relose, canoleboxy methino renolose Salts (such as carboxymethylcellulose, sodium carboxymethylcellulose and potassium carboxymethylcellulose), methinoresenolellose, ethylcellulose, polyacrylic acid, polyacrylate (sodium polyacrylate and acrylic acid / octyl acrylate co-polymer) ) And copolymers of methacrylic acid
  • cellulosic polymeric materials such as n-butyl polymer, methacrylic acid and methyl methacrylate polymer and methacrylic acid and ethyl acrylate polymer; carboxyvinyl polymer, polyethylene glycol, polyvinylpyrrolidone, Synthetic polymer materials such as polyvinyl alcohol; lectin, alginic acid, alginate (sodium alginate, potassium alginate, magnesium alginate, propylene glycol alginate ester, triethanolamine alginate, triisopropanolamine alginate, ammonium alginate Natural polymer substances such as sodium chondroitin sulfate, agar, chitosan and carrageenan; collagen and gelatin, etc.
  • Amino acid based polymeric material can arabic gum, Karaya gum, tragacanth gum, xanthan gum, locust bean gum, Guagamu, that our rubber-based polymer material such as the force present invention, such as tamarind gum and Jierangamu, Te suitably used.
  • Examples of the refreshing agent include 1-menthol, cQ-menthol, heart force oil, camphor, heart force water, borneol, peppermint essential oil, spearmint essential oil, and the like that can be used in the present invention. Any one of these can be used alone, or two or more can be used in combination.
  • binders include sugars (such as glucose), sugar alcohols (such as sorbitol, xylitol, erythritol, mannitol), polybulurpyrrolidone, starches, macrogol, dextrin, tragacanth, gelatin, polybulul alcohol, Shellac, gum arabic, sodium alginate, hydroxypropylcellulose, and the like are available in the present invention, but are not limited to these. The above can also be used together.
  • sweeteners include saccharin sodium, stepioside, stevia extract, and Asvalte.
  • Xylitol syrup, honey, sorbitol, maltitol, mannitol, saccharides (lactose, sucrose, fructose, glucose, etc.) can be used in the present invention, but are not limited thereto. Either one of these can be used, or two or more can be used in combination.
  • Natural flavors (spearmint oil, varnish oil, eucalyptus oil, wintergreen oil, cassia oil, clove oil, thyme oil, sage oil, lemon oil, orange oil, heart power oil, power rudamon oil, Coriander oil, mandarin oil, lime oil, lavender oil, rosemary oil, laurel oil, camomil oil, caraway oil, marjoram oil, bay oil, lemongrass oil, orina gum oil, pine-dollar oil, etc.), synthetic Fragrance (Carbon, Anethole, Cineol, Methyl salicylate, Cynamic aldehyde, Eugenol, Thymol, Linalol, Linalyl acetate, Limonene, Menthon, Menthyl acetate, Pinene, Octylaldehyde, Citral, Pregon, Calbele acetate, Anisaldehyde Natural fragrances listed above and , Or a blended fragrance obtained by mixing a fragrance arbitrarily selected
  • Examples of the disintegrant used in the present invention include starches, methylcellulose, crystalline cellulose, cellulose derivatives (such as sodium carboxymethylcellulose), alginic acid, alginates, carbonates, organic acids, polyvinyl pyrrolidone, and cross-linked polybutylpyrrolidone. It can be used, but not limited to these, only one of these can be used, or two or more can be used in combination.
  • Lubricants include talc, metal stalagmites, fatty acids (such as stearic acid), stearates (such as magnesium stearate), talc, sucrose fatty acid esters, hydrous silicon dioxide, light anhydrous key acid, dried Hydroxy-aluminum gel, macrogol, etc. can be used in the present invention, but are not limited to these, use only one of these V, or use two or more together You can also
  • blue 1, No. 4, titanium dioxide, copper chlorophyllin sodium and the like can be used in the invention of the present application. Can be used, or two or more types can be used in combination.
  • Preservatives include benzoic acids, salicylic acids, sorbic acids, norabens, cetylpyridinium chloride, decalinium chloride, benzethonium chloride, benzalkonium chloride, chlorhexidine chloride, chlorhexidine dalconate, isopropylmethylphenol, Forces that can be used in the present invention, such as trickle san, hinokitiol, phenol, etc., are not limited to these. Any one of these forces can be used, or two or more can be used in combination.
  • sustained release modifier polyvinyl acetate, ethyl cellulose, aminoalkyl metaacrylate copolymer and the like that can be used in the present invention S, and any one of these not limited to these 1 It is possible to use only one type or use both.
  • sucrose fatty acid ester polyoxyethylene hydrogenated castor oil, sorbitan monostearate, polysorbate, glyceryl monostearate, sodium lauryl sulfate, lauromacrogol and the like can be used in the present invention.
  • a certain force is not limited to these. Any one of these may be used, or two or more may be used in combination.
  • solubilizer glycerin, concentrated glycerin, propylene glycol, ethanol, fluidized ⁇ Raffin, purified water, macrogol, polysorbate, and the like can be used in the present invention, but are not limited thereto. Either one of these forces can be used, or two or more can be used in combination.
  • wetting agent glycerin, propylene glycol, sorbitol solution, water, ethanol, dilute ethanol and the like are not limited to these, and only one of these is used. Or, use two or more types together.
  • pH adjuster lactic acid, pantothenic acid, phosphate, malic acid, citrate, and the like can be used in the present invention. Can be used, or two or more types can be used in combination.
  • the dosage form of the oral composition of the present invention any of tablets, pills, granules, solutions, sheets, gels, pastes and the like can be used.
  • the oral cavity of the present invention When the composition for dental use is a dental preparation, it should be in the form of toothpaste, mouthwash, oral pasta, troche, etc. It can effectively cope with the prevention and treatment of oral diseases caused by destruction of periodontal tissues such as
  • Gingival epithelial tissue (about 5.0 mm ⁇ about 5.0 mm slice) was collected from the oral cavity of a healthy human gingival tissue. Collected tissue pieces are washed with phosphate buffer (1 X 10 5 U / ml).
  • DMEM / Ham's F12 medium (Dainippon Pharmaceutical Co., Ltd.) containing FBS, 10 pg / ml EGF, and 80 ⁇ g / ml kanamycin was gently poured into the well.
  • the culture system thus prepared was cultured under conditions of 37 ° C. and 5% carbon dioxide, and the primary culture medium was replaced with fresh one once every two days.
  • the medium is subcultured ( EDGS and EpiLife medium (casdade) containing 80 ⁇ g / ml kanamycin) were exchanged.
  • the culture solution was transferred to a type I collagen-coated T75 flask and subculture was performed at a cell density of 2500 cells / cm 2 according to the cell growth rate.
  • the gingival epithelial cells used in the following examples were obtained. Obtained
  • an inflammation induction medium for artificially inducing periodontitis was prepared.
  • Recombinant human TNF- ⁇ an inflammation-inducing substance, was purchased from PEPROTECH (Size B).
  • vial 50 ⁇ g, 300-01A; Lot No. 121CY25). 50 ⁇ g of recombinant human TNF-a at room temperature Then, after standing for 1 hour, it was applied to a desktop centrifuge. Dissolve the precipitate obtained by centrifugation in 500 ⁇ l of distilled water and add 0.1 mg / ml.
  • aqueous solution was further dissolved in 3.564 ml of physiological saline (PBS ( ⁇ )).
  • PBS physiological saline
  • the PBS solution thus obtained was dispensed in 1.2 ml portions into a serum tube and stored at a temperature of 120 ° C.
  • the remaining aqueous solution was dispensed 100 ⁇ l into a serum tube and stored at a temperature of 20 ° C.
  • cinnamon cinnamon extract powder was added to 0.02 g / ml (75% ethanol).
  • the solution containing the component extracted from Cypress japonica was filtered and sterilized using a 0.2 ⁇ m pore size filter, and the component concentration was adjusted using an inflammation-inducing medium.
  • the assay was performed according to the procedure reported in the literature of Inhibitors on Human ingival Cells and Porphyromonas gingivalis, .1. Periodontol. Vol.74, pp.1219-1224 (2003).
  • gingival epithelial cells are placed on a 24 well plate (1.8 cm 2 Zwell) at a ratio of 2 X 10 4 Zwell. Once every two days, the subculture medium was replaced with fresh one and the culture was continued until the cells covered the entire well. After confirming that the cells covered the entire well, half the cells of the well were scraped with the tip of the pipette tip. After washing the well with PBS, pour the inflammation-inducing medium and a solution containing extract components (1.0% or 0.1% concentration) from Cypress and cultivate under conditions of 37 ° C and 5% carbon dioxide. At the time of 0, 24, and 48 hours after the start of culturing, the photographs of the wells were taken to verify the degree of cell spreading (FIG.
  • the gingival epithelial cell growth-inhibiting effect by the extract derived from Japanese cypress is a remarkable inhibitory effect (+++), an inhibitory effect on strength (++)
  • the grading was performed according to a four-step evaluation of normal inhibitory effect (+) and no inhibitory effect (one). The evaluation results are summarized in Table 1 below.
  • LPS Escherichia coli
  • SIGMA protease from Streptomyces griseus
  • the rats were divided into a group of administration of cypress extract and a control group.
  • a group of administration of cinnamon extract two weeks after the start of LPS and protease treatment, O.lg of cereal extract extract (Western genus extract (75% ethanol extract: Omni force Co., Ltd.)) was added.
  • 1.5 1 of a 1% aqueous solution (0.2 mg / ml) of a solution obtained by dissolving in 75% ethanol with an aqueous solution obtained by diluting 5 times with distilled water was treated once a day for 2 weeks.
  • LPS and protease treatment was started and after 2 weeks, no treatment was performed.
  • test control tissue site was fixed (reflux + soaked), and after decalcification, it was embedded in paraffin to prepare a 4 m thick tongue-like section. Next, hematoxylin 'eosin staining was performed and microscopically observed to confirm the presence and extent of downgrowth of the gingival epithelial tissue.
  • a composition for oral cavity for various uses was prepared, which was prepared by blending an extract of Japanese cypress (1.0%), which demonstrated the effect of inhibiting the growth of gingival epithelial cells in Example B and Example C.
  • the unit of the component compounding amount in the present Example is indicated by weight% unless otherwise specified.
  • Toothpastes were prepared by mixing and kneading the materials shown in Table 3 below at room temperature.
  • a mouthwash was prepared by mixing the materials shown in Table 4 below at room temperature.
  • D-4 oral cavity The materials listed in Table 5 below were mixed at room temperature to prepare an oral pasta.
  • the agent for periodontal disease of the present invention is useful as a means for preventing and treating oral diseases such as gingivitis and periodontitis.
  • FIG. 1 is a schematic diagram for explaining the principle of a gingival epithelial cell extension inhibition test.
  • FIG. 2 is a schematic diagram illustrating the principle of extension of gingival epithelial tissue.
  • FIG. 3 is a photograph showing the extension state of gingival epithelial thread and tissue in (a) a control group and (b) a group of components extracted with Japanese horse chestnut extract.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Birds (AREA)
  • Medical Informatics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Cosmetics (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

Le problème à résoudre dans le cadre de cette invention consiste à fournir un nouveau médicament pour la maladie parodontale qui présente un excellent effet inhibiteur sur l'extension anormale du tissu épithélial gingival. La solution proposée consiste à fournir un nouveau médicament pour la maladie parodontale, contenant un composant obtenu par l'extraction d'Aesculus hippocastanum L. au moyen d'un solvant et par isolement; ainsi qu'une composition destinée à une utilisation dans la cavité buccale pour le traitement de maladies buccales telles que la gingivite et la parodontite, qui contient le médicament précité.
PCT/JP2006/306978 2005-03-31 2006-03-31 Medicament pour maladie parodontale comprenant un composant extrait de aesculus hippocastanum l. WO2006106994A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2005103745A JP2006282562A (ja) 2005-03-31 2005-03-31 セイヨウトチノキの抽出成分を配合した歯周病用剤
JP2005-103745 2005-03-31

Publications (2)

Publication Number Publication Date
WO2006106994A1 true WO2006106994A1 (fr) 2006-10-12
WO2006106994A8 WO2006106994A8 (fr) 2009-08-27

Family

ID=37073544

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2006/306978 WO2006106994A1 (fr) 2005-03-31 2006-03-31 Medicament pour maladie parodontale comprenant un composant extrait de aesculus hippocastanum l.

Country Status (2)

Country Link
JP (1) JP2006282562A (fr)
WO (1) WO2006106994A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011020935A (ja) * 2009-07-14 2011-02-03 Lotte Co Ltd ラクチトール、マルチトールからなる抗菌剤

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230033488A (ko) * 2021-09-01 2023-03-08 주식회사 안지오랩 칠엽수 추출물을 포함하는 조성물

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5758613A (en) * 1980-09-26 1982-04-08 Lion Corp Composition for oral cavity application
JPS5782307A (en) * 1980-11-12 1982-05-22 Lion Corp Composition for oral purpose
JPS59101419A (ja) * 1982-11-06 1984-06-12 ブレンダツクス−ベルケ　ア−ル。シユナイダ−　ゲゼルシヤフト　ミツト　ベシユレンクテル　ハフツンク　ウント　コンパニ− 歯および口の保健薬製剤
KR0138248B1 (ko) * 1992-10-07 1998-05-15 최근선 식물 추출물을 함유한 구강위생 증진용 조성물
JPH11222419A (ja) * 1997-12-02 1999-08-17 Lion Corp 口腔用組成物
JP2001139475A (ja) * 1999-10-08 2001-05-22 L'oreal Sa エスシンとデキストラン硫酸の組合せ及びそれらの用途
WO2003035092A1 (fr) * 2001-10-26 2003-05-01 Angiolab Inc. Composition contenant un extrait de marron d'inde preparee pour son activite anti-angiogenique et inhibitrice de metalloproteinase matricielle
JP2004520294A (ja) * 2000-12-12 2004-07-08 アンジオラボ・インコーポレイテッド 抗−血管新生およびマトリックスメタロプロテイナーゼ阻害活性を有するメリッサ葉抽出物を含む組成物

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5758613A (en) * 1980-09-26 1982-04-08 Lion Corp Composition for oral cavity application
JPS5782307A (en) * 1980-11-12 1982-05-22 Lion Corp Composition for oral purpose
JPS59101419A (ja) * 1982-11-06 1984-06-12 ブレンダツクス−ベルケ　ア−ル。シユナイダ−　ゲゼルシヤフト　ミツト　ベシユレンクテル　ハフツンク　ウント　コンパニ− 歯および口の保健薬製剤
KR0138248B1 (ko) * 1992-10-07 1998-05-15 최근선 식물 추출물을 함유한 구강위생 증진용 조성물
JPH11222419A (ja) * 1997-12-02 1999-08-17 Lion Corp 口腔用組成物
JP2001139475A (ja) * 1999-10-08 2001-05-22 L'oreal Sa エスシンとデキストラン硫酸の組合せ及びそれらの用途
JP2004520294A (ja) * 2000-12-12 2004-07-08 アンジオラボ・インコーポレイテッド 抗−血管新生およびマトリックスメタロプロテイナーゼ阻害活性を有するメリッサ葉抽出物を含む組成物
WO2003035092A1 (fr) * 2001-10-26 2003-05-01 Angiolab Inc. Composition contenant un extrait de marron d'inde preparee pour son activite anti-angiogenique et inhibitrice de metalloproteinase matricielle

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
OGURA M. ET AL.: "Horse Chestnut Shushi Saponin (Amorphous Aescin) no Koensho Sayo", PHARMACOMETRICS, vol. 9, no. 6, 1975, pages 883 - 894, XP003004592 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011020935A (ja) * 2009-07-14 2011-02-03 Lotte Co Ltd ラクチトール、マルチトールからなる抗菌剤

Also Published As

Publication number Publication date
JP2006282562A (ja) 2006-10-19
WO2006106994A8 (fr) 2009-08-27

Similar Documents

Publication Publication Date Title
TWI438006B (zh) 含蜂膠之口腔用組成物
US20140378547A1 (en) Antioxidant compositions for treatment of inflammation or oxidative damage
JP2021100975A (ja) 歯周組織再生剤、歯周組織再生方法、歯周組織増殖・活性化剤及び歯周組織アンチエージング剤
JP2022093452A (ja) 口腔用組成物
JP2016216419A (ja) 歯周病改善剤及びその製造方法
JP2023068100A (ja) 歯肉ケア方法
US7846422B2 (en) Method for prevention or treatment of periodontal diseases and composition for an oral cavity
JP2002029953A (ja) 歯周病の予防または治療用の食品組成物、口腔用組成物
WO2006106996A1 (fr) Inhibiteur de la proliferation de cellules epitheliales gingivales
WO2006106994A1 (fr) Medicament pour maladie parodontale comprenant un composant extrait de aesculus hippocastanum l.
JP2011063556A (ja) 口腔内細菌の共凝集阻害剤及びそれを配合した口腔用組成物
WO2021033661A1 (fr) Activateur de cellules épithéliales gingivales
JP3008525B2 (ja) 口腔用組成物
JP2005035907A (ja) 抗歯周病剤
WO2006106995A1 (fr) Inhibiteur de la metalloproteinase comprenant un ingredient extrait d’amula
KR101270704B1 (ko) 석이버섯 추출물을 유효성분으로 함유하는 구강용 조성물
WO2007037492A1 (fr) Agent thérapeutique pour une parodontopathie contenant un ingrédient extrait d’une plante appartenant à la famille des salicacées, genre salix
JP2000191487A (ja) マトリクスメタロプロテア―ゼ阻害用口腔剤組成物及び飲食品組成物
JP6030069B2 (ja) 歯周病の予防及び／又は治療のための口腔内洗浄用組成物
JP2011121920A (ja) エラスターゼ阻害剤並びにそれを含有する化粧品組成物及び医薬品組成物
JP2015071623A (ja) オレウロペインおよびその分解物を含有する歯周組織健康維持剤
JPH10306019A (ja) 口腔用組成物
JP3647296B2 (ja) チロシナーゼ活性阻害およびこれを含有する組成物
JP7424770B2 (ja) 歯肉組織破壊抑制剤
KR101344803B1 (ko) 후박 추출물과 금속이온 봉쇄제를 포함하는 구강 위생용 조성물

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

NENP Non-entry into the national phase

Ref country code: RU

122 Ep: pct application non-entry in european phase

Ref document number: 06730926

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: JP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载